Management of Polycystic Ovary Syndrome (PCOS) with Alternatives to Rosiglitazone

Primary Alternative: Metformin

The American College of Physicians recommends metformin as the first-line treatment for PCOS, due to its superior metabolic profile and ability to improve insulin sensitivity, with a daily dose of 1.5-2 g, divided into twice-daily administration 1, 2
Metformin tends to decrease weight, while thiazolidinediones, including rosiglitazone, cause weight gain—a critical distinction given obesity's role in exacerbating PCOS, as noted by the American Family Physician 3, 1
Metformin improves insulin sensitivity by decreasing hepatic gluconeogenesis and increasing peripheral glucose uptake, which subsequently reduces ovarian androgen production and lowers circulating testosterone, according to the Endocrine Society 1, 2
Metformin maintains or improves glucose tolerance over time in women with PCOS, even with normal HbA1c values, as recommended by the American Diabetes Association 1
Metformin decreases LDL cholesterol and triglyceride levels, providing cardiovascular benefits, as suggested by the American Heart Association 1
Metformin normalizes ovulatory abnormalities and improves ovulation frequency, according to the American Society for Reproductive Medicine 1, 2

The Obesity Society recommends GLP-1 receptor agonists, such as liraglutide and semaglutide, as emerging alternatives for women with obesity or inadequate response to metformin, due to their ability to promote weight loss and improve metabolic parameters 5, 6, 2
Liraglutide and semaglutide appear superior to placebo for anthropometric outcomes, based on descriptive analyses from the 2024 International Evidence-based Guideline systematic review, as noted by the National Institutes of Health 5, 6
GLP-1 receptor agonists promote weight loss through multiple mechanisms, including suppression of postprandial glucagon, inhibition of glucose production, slowed gastric emptying, and increased satiety, according to the European Association for the Study of Obesity 5, 6

The American College of Obstetricians and Gynecologists recommends a treatment algorithm for PCOS, starting with metformin 1.5-2 g daily, plus lifestyle modification targeting 5% weight loss, as the first-line treatment for metabolic and androgenic management 1, 2
The algorithm suggests adding a GLP-1 receptor agonist, such as liraglutide or semaglutide, as a second-line treatment for women with obesity or inadequate response to metformin, as recommended by the Endocrine Society 5, 6, 2
The algorithm also recommends considering orlistat as an adjunctive therapy for additional weight loss support, according to the American Society for Metabolic and Bariatric Surgery 2

The American Family Physician warns against combining metformin with thiazolidinediones, due to the lack of additional metabolic benefit and increased risk of weight gain 3
The American College of Obstetricians and Gynecologists advises against continuing metformin into pregnancy without careful consideration of emerging evidence showing adverse offspring metabolic outcomes, as noted by the National Institutes of Health 4
The American Society for Reproductive Medicine recommends against using metformin as first-line for fertility, as clomiphene is significantly more effective, according to the Endocrine Society 4
The American Heart Association emphasizes the importance of lifestyle modification, even a 5% weight loss, to enhance all pharmacological interventions, as recommended by the American College of Sports Medicine 3, 1, 2